End-to-End CGT Vineti's PTM platform provides end-to-end supply chain management for cell and gene therapies, enabling patient-to-product workflows and scalable delivery. This makes it attractive to biotech and pharma developers launching CGTs who need an enterprise platform to manage manufacturing, quality, logistics and regulatory controls across sites. The platform emphasizes on-time delivery and traceability, addressing a critical pain point in CGT commercialization.

Strategic Partnerships The company maintains active collaborations with ecosystem players such as Korber Group (Werum PAS-X), Autolomous, SedApta, and Be The Match BioTherapies. These partnerships provide credibility and create joint go-to-market opportunities to sell integrated PTM solutions to customers already using these platforms.

Integration Readiness Vineti launched the Integration Suite to anchor PTM and enable interoperability with ERP and MES systems, supported by a tech stack including Salesforce, SQL and WSO2. This reduces integration risk for complex CGT manufacturing environments and makes the platform attractive to CIOs and procurement teams seeking seamless data flows.

Market Opportunity The CGT market is expanding and Vineti positions itself as a leading digital platform of record for personalized therapeutics. With ongoing partnerships and a funding base, there is clear leverage to scale adoption among biotech developers, CMOs and healthcare providers seeking end-to-end CGT supply chain control.

Leadership Momentum CEO Ann Klein joined in 2022, supported by a board role and strategic partnerships, signaling strong leadership momentum. A small, agile team coupled with investor backing and ecosystem collaborations supports a credible path to rapid growth and scalable sales execution.